NEW YORK (Reuters Health)—Compared with cyclophosphamide, rituximab treatment poses less malignancy risk in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), European researchers report. Dr. Emma E. van Daalen of Leiden University Medical Center in the Netherlands tells Reuters Health, “Previous studies reported an increased malignancy risk in patients with AAV, which has been associated…
FDA Update on Rituximab & Etanercept; Plus New ACP Gout Guideline
The FDA is considering an application for subcutaneous rituximab and has approved an application for etanercept to treat pediatric patients with plaque psoriasis…
Reinitiating TNF Blockers after Tuberculosis Treatment
A retrospective study showed that patients who have rheumatic disease and develop tuberculosis may be able to resume anti-TNF therapy and other biologic agents…
Remission of Rheumatoid Arthritis Tied to Lower Risk of Metabolic Syndrome
NEW YORK (Reuters Health)—Disease remission in patients with rheumatoid arthritis (RA) is associated with a lower risk of developing metabolic syndrome, according to a new study from Thailand. Researchers also found that a lower educational level was linked to a higher risk of metabolic syndrome, they report in Joint Bone Spine, online May 26. Dr….
Roche & Novartis Face Off in Biosimilar Drug Battle
ZURICH (Reuters)—Switzerland’s biggest drugmakers are clashing over cheaper copies of pricey biotech drugs—one reason why Novartis is considering selling its $14 billion stake in cross-town rival Roche. With a copycat of Roche’s blood cancer drug Rituxan (rituximab) pending European approval, Novartis aims to muscle in on a share of sales that last year hit 7…
Does Methotrexate Increase Skin Cancer Risk?
A recent study connects the use of immunosuppressant and biologic agents to an increased risk of nonmelanoma skin cancer in patients being treated for RA and IBD…
Rituximab May Benefit Patients with Refractory JIA-Associated Uveitis
NEW YORK (Reuters Health)—Rituximab may calm juvenile idiopathic arthritis (JIA)-associated uveitis and especially benefit patients who haven’t responded to other biologic treatments, a study from Italy suggests. With its convenient dosing schedule, rituximab may be a new treatment option for patients with autoimmune diseases, especially for those who have not responded to tumor necrosis factor…
Immunotherapy May Be Effective for Some Patients with Autoimmune Cerebellar Ataxia
NEW YORK (Reuters Health)—Immunotherapy appears to yield neurological improvements in some patients with autoimmune cerebellar ataxia, especially those with nonparaneoplastic disorders, researchers report. “I was surprised that so many patients responded to immunotherapy (steroids, intravenous immunoglobulin (IVIg), and plasma exchange) and remained ambulatory,” Dr. Andrew McKeon from Mayo Clinic in Rochester, Minn., told Reuters Health…
Rituximab for RA Is Safe Long Term, Plus Oxycodone Update
Rituximab was evaluated and found safe as a long-term RA therapy. Also, FDA Advisory Committees voted on oxycodone therapies at a joint meeting.
Hepatitis Reaction with Rituximab Sparks Drug Safety Alert
The FDA modifies rituximab prescribing information to stress risk of hepatitis B virus reactivation
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- Next Page »